Tempest Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPST research report →
Price Chart
About the company
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications.
- CEO
- Matthew Angel
- IPO
- 2012
- Employees
- 4
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on TPST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.57M
- P/E
- -0.18
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -10.99
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1270.11%
- ROIC
- -628.18%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-26,575,000
- Net Income
- $-26,262,000+37.2%
- EPS
- $-6.33-322.0%
- OCF Growth
- +18.8%
- FCF Growth
- +19.8%
- 52W High
- $12.23
- 52W Low
- $0.74
- 50D MA
- $0.96
- 200D MA
- $1.72
- Beta
- -1.71
- RSI (14)
- 44
- Avg Volume
- 2.59M
No earnings-call transcripts are available for TPST yet.
- Free Float
- 60.1%
- Shares Outstanding
- 15.98M
- Float Shares
- 9.61M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sabby Management, LLC | 511.29K | ▲ 493.43K |
| Vanguard Capital Management LLC | 233.89K | 0 |
| Vanguard Group Inc | 162.56K | 0 |
| Geode Capital Management, LLC | 86.63K | ▼ 365 |
| Vanguard Fiduciary Trust Co | 68.91K | 0 |
| Blackrock, Inc. | 39.07K | 0 |
| Squarepoint Ops LLC | 30.90K | ▲ 30.90K |
| Northern Trust Corp | 20.14K | ▲ 6.08K |
| Citadel Advisors LLC | 19.82K | ▲ 19.82K |
| Ubs Group AG | 5.64K | ▲ 1.10K |
| Tower Research Capital LLC (Trc) | 3.92K | ▲ 1.13K |
| Morgan Stanley | 2.02K | ▼ 36 |
Held by 19 ETFs
Biggest fund positions in TPST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 22, 26 | Smith Nancy Freda | other | 25,000 |
| Sep 22, 26 | Smith Nancy Freda | other | 0 |
| Mar 24, 26 | Angel Matthew | buy | 231,482 |
| Mar 24, 26 | Angel Matthew | buy | 231,482 |
| Jun 4, 26 | Yee John D. | other | 25,000 |
| Jun 4, 26 | Yee John D. | other | 0 |
| Jun 4, 26 | Richey William Drake | other | 0 |
| Jun 4, 26 | Richey William Drake | other | 25,000 |
| Mar 31, 26 | Trojanowski Justin | other | 22,000 |
| Mar 31, 26 | Maestas Nicholas | other | 140,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TPST coverage
Recent articles, reports, and earnings notes.
No research on TPST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TPST report →Tempest signs related-party R&D pact, reshapes leadership
defenseworld.net · Sep 29
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
globenewswire.com · Sep 23
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
benzinga.com · Sep 16
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
globenewswire.com · Sep 15
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
globenewswire.com · Sep 11
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 13
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
globenewswire.com · Jul 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.